How to take Revuforj (Revumenib)

A new therapy called Revuforj (Revumenib) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory acute leukemia with KMT2A translocation. This includes adult and pediatric patients one year and older. Up to 15% of patients with acute leukemia have the KMT2A gene translocation in their cancer cells. This mainly affects acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Acute leukemia patients treated with Revuforj were selected based on the presence of the KMT2A translocation in bone marrow cells There are currently no FDA-approved companion diagnostics for the detection of KMT2A translocations. The recommended dose of Revuforj varies based on patient weight and concomitant use of strong CYP3A4 inhibitors. Do not start taking Revuforj until your white blood cells have dropped below 25 Gi/L. Continue taking Revuforj until disease progression or unacceptable toxicity occurs. For patients without disease progression or unacceptable toxicity, treat for at least 6 months to allow time to achieve clinical response.

The starting dose for patients weighing 40 kg or more is 270 mg orally twice daily; for patients weighing less than 40 kg, the starting dose is 160 mg/m3 orally twice daily; recommended dose for patients 1 year and older Follow your doctor's advice.

Patients are required to take Revuforj twice daily without food or with a low-fat meal (e.g., a meal containing approximately 25% fat or less). Take by mouth at approximately the same time each day. Patients are advised to swallow the tablets whole and not to cut or chew the tablets. If the patient is unable to swallow the tablets, they can be crushed and dispersed in water and taken within 2 hours of preparation. If a dose of Revuforj is missed or not taken at the usual time, the dose should be taken as soon as possible on the same day and at least 12 hours before the next scheduled dose. Back to normal schedule the next day. Do not take 2 doses within 12 hours.

Assess blood counts, electrolytes, and liver enzymes before starting Revuforj and monthly thereafter. Before starting Revuforj, perform an EKG at least once a week (for the first 4 weeks) and at least once a month thereafter. Monitor for QTc interval prolongation and promptly address any abnormalities.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6eb3cdbc-0e74-477d-82d6-3bb172d3f63f